Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease.

Authors

Usama Gergis MD, MBA, Lehigh Valley Health NetworkFollow
Jon Arnason
Rhonda Yantiss
Tsiporah Shore
Usama Wissa
Eric Feldman
Thasia Woodworth

Publication/Presentation Date

10-20-2010

Volume

28

Issue

30

First Page

602

Last Page

604

ISSN

1527-7755

Published In/Presented At

Gergis, U., Arnason, J., Yantiss, R., Shore, T., Wissa, U., Feldman, E., & Woodworth, T. (2010). Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(30), e602–e604. https://doi.org/10.1200/JCO.2010.29.1682

Disciplines

Medicine and Health Sciences

PubMedID

20713858

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute

Document Type

Article